pharmaphorum November 8, 2023
Novo Nordisk is finally facing some major competition to its obesity franchise juggernaut, now that Eli Lilly’s rival therapy tirzepatide has been approved by the FDA as a weight-loss drug.
Already a blockbuster as a therapy for type 2 diabetes under the Mounjaro brand name, dual GLP-1/GIP agonist tirzepatide has been cleared for obesity as Zepbound, paving the way for a big increase in sales and setting up a battle for market share with Novo Nordisk’s GLP-1 agonist Wegovy (semaglutide).
The FDA has approved Zepbound for chronic weight management in adults who are obese with a body mass index of 30 or more, or overweight with a BMI of at least 27 and at least one weight-related health condition, such...
Today's Sponsors
Today's Sponsor